Related Experiment Video
Updated: Mar 22, 2026
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
[Role of miR-663 in acute renal graft rejection: an in vitro study]
Xiao-You Liu1, Jie Zhang, Jie Liang
1Department of OrganTransplantation, ZhujiangHospital, Southern Medical University Guangzhou 510282, China.E-mail: liuxy@fimmu.com.
Objective:
To compare the serum miR-663 levels in renal transplant patients with and without acute rejection (AR) and explore the role of miR-663 acute renal graft rejection.
Methods:
Real time-PCR was used to determine serum miR-663 levels in renal transplant recipients with and without AR. MTT assay and Annexin V-FITC assay were employed to examine the viability and apoptosis of human renal glomerular endothelial cells (HRGEC) treated with a miR-663 mimic or a miR-663 inhibitor, and ELISA was performed to detect the expression of inflammation-related cytokines including IL-6, IFN-γ, CCL-2 and TNF-α in the cells. Transwell assay was used to examine the effect of miR-663 mimic and miR-663 inhibitor on the chemotactic capability of macrophages.
Results:
Serum miR-663 level was significantly higher in renal transplant recipients with AR than in those without AR. The miR-663 mimic significantly inhibited the viability of HRGECs and increase the cell apoptosis rate, while miR-663 inhibitor suppressed the cell apoptosis. The miR-663 mimic increased the expression levels of inflammation-related cytokines and enhanced the chemotactic capability of macrophages.
Conclusion:
miR-663 might play important roles in acute renal graft rejection and may become a therapeutic target for treating AR.
Insights
Serum miR-663 levels are elevated in renal transplant recipients experiencing acute rejection (AR). This microRNA (miRNA) may promote AR by increasing inflammation and cell death, suggesting it as a potential therapeutic target.
Area of Science:
- Nephrology
- Molecular Biology
- Immunology
Background:
- Acute rejection (AR) remains a significant challenge in renal transplantation.
- Biomarkers for early detection and therapeutic targets are crucial for improving graft survival.
Purpose of the Study:
- To compare serum miR-663 levels in renal transplant patients with and without AR.
- To investigate the functional role of miR-663 in acute renal graft rejection.
Main Methods:
- Serum miR-663 levels were quantified using real-time PCR.
- In vitro studies involved human renal glomerular endothelial cells (HRGECs) treated with miR-663 mimic/inhibitor.
- Cell viability, apoptosis, cytokine expression (IL-6, IFN-γ, CCL-2, TNF-α), and macrophage chemotaxis were assessed.
Main Results:
- Serum miR-663 levels were significantly higher in patients with AR.
- miR-663 mimic reduced HRGEC viability and increased apoptosis, while the inhibitor had the opposite effect.
- miR-663 mimic elevated pro-inflammatory cytokines and enhanced macrophage chemotaxis.
Conclusions:
- miR-663 is implicated in the pathogenesis of acute renal graft rejection.
- miR-663 may serve as a potential diagnostic biomarker and therapeutic target for AR.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management